Update from Arcede Pharma CEO
Arcede Pharma develops RCD405, a dual-action drug candidate for the treatment of COPD and severe asthma. The company is underway with the final part of the preclinical development, where it is waiting for final results from the toxicology program. Recently, the team was expanded with two scientific advisors, both leading experts in the respiratory field. In an interview in connection with the BioStock Investor Meeting, Arcede Pharma’s CEO Mia Lundblad gave an update.
Watch the interview (in Swedish) with Arcede Pharma CEO Mia Lundblad below:
Don´t miss Mia’s presentation at BioStock Investor Meeting:
Learn more about Arcede Pharma here.
Learn more about BioStock Investor Meeting here.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.